ArticlePharmaceutics2024
miR-195-5p Inhibits Colon Cancer Progression via KRT23 Regulation.
Article in Pharmaceutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it.
- MicroRNAs and Cellular Senescence in Melanoma: An Underexplored Link to Tumor Progression-A Systematic Review with Bioinformatics Analyses.International journal of molecular sciences · 2026Pooled it
- KRT23 promotes proliferation invasion and metastasis of gastric cancer through epithelial-mesenchymal transition mediated by the PI3K/AKT/mTOR signaling pathway.Translational cancer research · 2025Article
- Exploring miRNA Research in Colorectal Cancer: Insights from a Bibliometric Analysis.Pharmaceutics · 2025Article
- MicroRNA Signatures in Lung Adenocarcinoma Metastases: Exploring the Oncogenic Targets of Tumor-SuppressiveCancers · 2025Article
- Article
- miR-369-3p Ameliorates Inflammation and Apoptosis in Intestinal Epithelial Cells via the MEK/ERK Signaling Pathway.International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
BACKGROUND/
objectivesKRT23 was recently discovered as an epithelial-specific intermediate filament protein in the type I keratin family. Many studies have underlined keratin's involvement in several biological processes as well as in the pathogenesis of different diseases. Specifically, KRT23 was reported to affect the structural integrity of epithelial cells and to trigger cellular signaling leading to the onset of cancer. The aim of this study is to characterize a novel mechanism based on miR-195-5p/KRT23 in colorectal cancer.
methodsKRT23 mRNA and protein expression were characterized in FFPE sections from patients with CRC. The effects of miR-195-5p on KRT23 expression at the mRNA and protein levels were assessed by transient transfection experiments with mimic and inhibitor molecules. Cell attachment/detachment, migration, invasion, clone formation, and apoptosis were evaluated in human CRC cell lines after miR-195-5p mimic transfection.
resultsWe identified KRT23 as a putative target of miR-195-5p, a microRNA that we previously demonstrated to be reduced in CRC. We have proved the KRT23 expression deregulation in the tumoral section compared to adjacent normal mucosa in patients with CRC, according to the data derived from the public repository. We proved that the gain of miR-195-5p decreased the KRT23 expression. Conversely, we demonstrated that the inhibition of miR-195-5p led to an increase in KRT23 expression levels. We have demonstrated the in vitro effectiveness of miR-195-5p on CRC progression and that the in vivo intraperitoneal delivery of miR-195-5p mimic lowered colonic KRT23 mRNA and protein expression.
conclusionsThese findings highlight a new regulatory mechanism by miR-195-5p in CRC affecting the keratin intermediate filaments and underline the miR-195-5p potential clinical properties.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.